Mycolactone Diffuses into the Peripheral Blood of Buruli Ulcer Patients - Implications for Diagnosis and Disease Monitoring

被引:42
作者
Sarfo, Fred S. [1 ]
Le Chevalier, Fabien [2 ]
Aka, N'Guetta [3 ]
Phillips, Richard O. [1 ,4 ]
Amoako, Yaw [1 ]
Boneca, Ivo G. [2 ,5 ]
Lenormand, Pascal [2 ]
Dosso, Mireille [3 ]
Wansbrough-Jones, Mark [6 ]
Veyron-Churlet, Romain [2 ]
Guenin-Mace, Laure [2 ]
Demangel, Caroline [2 ]
机构
[1] Komfo Anokye Teaching Hosp, Kumasi, Ghana
[2] Inst Pasteur, Paris, France
[3] Inst Pasteur, Abidjan, Cote Ivoire
[4] Kwame Nkrumah Univ Sci & Technol, Kumasi, Ghana
[5] INSERM, Grp AVENIR, Paris, France
[6] St Georges Univ London, London, England
关键词
MYCOBACTERIUM-ULCERANS; ANTIBIOTIC-TREATMENT; CYTOKINE PRODUCTION; CLINICAL-EFFICACY; STREPTOMYCIN; COMBINATION; RIFAMPIN; TOXIN; SUPPRESSION; INFECTION;
D O I
10.1371/journal.pntd.0001237
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Mycobacterium ulcerans, the causative agent of Buruli ulcer (BU), is unique among human pathogens in its capacity to produce a polyketide-derived macrolide called mycolactone, making this molecule an attractive candidate target for diagnosis and disease monitoring. Whether mycolactone diffuses from ulcerated lesions in clinically accessible samples and is modulated by antibiotic therapy remained to be established. Methodology/Principal Finding: Peripheral blood and ulcer exudates were sampled from patients at various stages of antibiotic therapy in Ghana and Ivory Coast. Total lipids were extracted from serum, white cell pellets and ulcer exudates with organic solvents. The presence of mycolactone in these extracts was then analyzed by a recently published, field-friendly method using thin layer chromatography and fluorescence detection. This approach did not allow us to detect mycolactone accurately, because of a high background due to co-extracted human lipids. We thus used a previously established approach based on high performance liquid chromatography coupled to mass spectrometry. By this means, we could identify structurally intact mycolactone in ulcer exudates and serum of patients, and evaluate the impact of antibiotic treatment on the concentration of mycolactone. Conclusions/Significance: Our study provides the proof of concept that assays based on mycolactone detection in serum and ulcer exudates can form the basis of BU diagnostic tests. However, the identification of mycolactone required a technology that is not compatible with field conditions and point-of-care assays for mycolactone detection remain to be worked out. Notably, we found mycolactone in ulcer exudates harvested at the end of antibiotic therapy, suggesting that the toxin is eliminated by BU patients at a slow rate. Our results also indicated that mycolactone titres in the serum may reflect a positive response to antibiotics, a possibility that it will be interesting to examine further through longitudinal studies.
引用
收藏
页数:8
相关论文
共 26 条
  • [1] Laboratory diagnosis of Buruli ulcer disease
    Beissner, Marcus
    Herbinger, Karl-Heinz
    Bretzel, Gisela
    [J]. FUTURE MICROBIOLOGY, 2010, 5 (03) : 363 - 370
  • [2] Mycolactone Suppresses T Cell Responsiveness by Altering Both Early Signaling and Posttranslational Events
    Boulkroun, Sheerazed
    Guenin-Mace, Laure
    Thoulouze, Maria-Isabel
    Monot, Marc
    Merckx, Anais
    Langsley, Gordon
    Bismuth, Georges
    Di Bartolo, Vincenzo
    Demangel, Caroline
    [J]. JOURNAL OF IMMUNOLOGY, 2010, 184 (03) : 1436 - 1444
  • [3] Callaway T R, 2004, Curr Issues Intest Microbiol, V5, P19
  • [4] Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease)v
    Chauty, Annick
    Ardant, Marie-Francoise
    Adeye, Ambroise
    Euverte, Helene
    Guedenon, Augustin
    Johnson, Christian
    Aubry, Jacques
    Nuermberger, Eric
    Grosset, Jacques
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (11) : 4029 - 4035
  • [5] Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans:: the contribution of endogenous mycolactone toxin
    Coutanceau, E
    Marsollier, L
    Brosch, R
    Perret, E
    Goossens, P
    Tanguy, M
    Cole, ST
    Small, PLC
    Demangel, C
    [J]. CELLULAR MICROBIOLOGY, 2005, 7 (08) : 1187 - 1196
  • [6] Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone
    Coutanceau, Emmanuelle
    Decalf, Jeremie
    Martino, Angelo
    Babon, Aurelie
    Winter, Nathalie
    Cole, Stewart T.
    Albert, Matthew L.
    Demangel, Caroline
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2007, 204 (06) : 1395 - 1403
  • [7] Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans
    Demangel, Caroline
    Stinear, Timothy P.
    Cole, Stewart T.
    [J]. NATURE REVIEWS MICROBIOLOGY, 2009, 7 (01) : 50 - 60
  • [8] Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of buruli ulcer in humans
    Etuaful, S
    Carbonnelle, B
    Grosset, J
    Lucas, S
    Horsfield, C
    Phillips, R
    Evans, A
    Ofori-Adjei, D
    Klustse, E
    Owusu-Boaten, J
    Amedofu, GK
    Awuah, P
    Arnpadu, E
    Amofah, G
    Asiedu, K
    Wansbrough-Jones, A
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (08) : 3182 - 3186
  • [9] Mycolactone:: A polyketide toxin from Mycobacterium ulcerans required for virulence
    George, KM
    Chatterjee, D
    Gunawardana, G
    Welty, D
    Hayman, J
    Lee, R
    Small, PLC
    [J]. SCIENCE, 1999, 283 (5403) : 854 - 857
  • [10] All-Oral Antibiotic Treatment for Buruli Ulcer: A Report of Four Patients
    Gordon, Claire L.
    Buntine, John A.
    Hayman, John A.
    Lavender, Caroline J.
    Fyfe, Janet A. M.
    Hosking, Patrick
    Starr, Mike
    Johnson, Paul D. R.
    [J]. PLOS NEGLECTED TROPICAL DISEASES, 2010, 4 (11):